Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.308 SEK | -2.53% | -0.96% | -24.42% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.65M | Sales 2022 | 3.04M 279K | Capitalization | 234M 21.46M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.22M | Net income 2022 | -357M -32.81M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 7.98M | Net cash position 2022 | 134M 12.35M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | -2.53% | ||
1 week | -0.96% | ||
Current month | -0.81% | ||
1 month | -0.32% | ||
3 months | -3.14% | ||
6 months | +39.05% | ||
Current year | -24.42% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.308 | -2.53% | 62 697 |
24-04-17 | 0.316 | +4.64% | 212,212 |
24-04-16 | 0.302 | -2.27% | 743,158 |
24-04-15 | 0.309 | +0.49% | 342,352 |
24-04-12 | 0.3075 | -1.13% | 635,347 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 05:14 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.42% | 15.47M | |
+28.79% | 676B | |
+24.95% | 554B | |
-7.64% | 349B | |
+15.00% | 318B | |
+5.99% | 291B | |
+3.26% | 210B | |
-0.25% | 204B | |
-9.73% | 194B | |
-11.71% | 144B |
- Stock Market
- Equities
- VIVE Stock